Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

北控醫療健康產業集團有限公司
Beijing Enterprises Medical And Health Industry Group Limited

(Incorporated in the Cayman Islands with limited liability)
(Stock Code: 2389)

PROFIT WARNING

This announcement is made by Beijing Enterprises Medical and Health Industry Group Limited (the "**Company**", together with its subsidiaries as the "**Group**") pursuant to Rule 13.09(2)(a) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the "**Listing Rules**") and the Inside Information Provisions (as defined under the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Cap. 571, Laws of Hong Kong).

The board of directors (the "**Board**") of the Company wishes to inform the shareholders of the Company (the "**Shareholders**") and potential investors of the Company that based on the preliminary review and assessment of the Group's unaudited consolidated management accounts, it is expected that the Group will record a decrease in the consolidated profit for the year of over 90% for the year ended 31 December 2018 (the "**Financial Year 2018**"), as compared to that for the year ended 31 December 2017 (the "**Financial Year 2017**") or record a loss for the Financial Year 2018. Such decrease is mainly due to (i) the one-off gain before tax on disposal of assets for the Financial Year 2017 of approximately HK$576,000,000, as compared to that of approximately HK$206,000,000 for the Financial Year 2018; and (ii) the one-off impairment provision for non-cash assets of approximately HK$35,000,000 in the Financial Year 2018.

The anticipated consolidated profit for the year is only a preliminarily anticipated figure and may be subject to impairment of assets, changes in the valuation of investment properties, ultimate share of profits/losses of associates, adjustment of gains from the disposal of equity interests and other audit adjustments during the audit process. The Company is still in the process of finalizing the consolidated annual results for the Financial Year 2018, which is subject to further adjustments.

The information contained in this announcement is only a preliminary assessment by the management of the Company based on the figures and information made available as at the date hereof and is not based on any figures or information which has been audited by the Company's auditor. The information regarding the finalized consolidated annual results of the Company and other details will be disclosed in the 2018 annual report to be published by the Company. There may be differences between such information and the information set out above.

Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.

By order of the Board
Beijing Enterprises Medical and Health Industry Group Limited
Zhu Shi Xing
Chairman

Hong Kong, 27 February 2019

As at the date of this announcement, the Board comprises seven Executive Directors, namely Mr. Zhu Shi Xing, Mr. Liu Xue Heng, Mr. Gu Shan Chao, Mr. Siu Kin Wai, Mr. Hu Shiang Chi, Mr. Wang Zheng Chun and Mr. Zhang Jing Ming; and five Independent Non-Executive Directors, namely Mr. Robert Winslow Koepp, Mr. Gary Zhao, Mr. Tse Man Kit, Keith, Mr. Wu Yong Xin, and Mr. Zhang Yun Zhou.